Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 26(29): 4319-28, 2007 Jun 21.
Article in English | MEDLINE | ID: mdl-17260023

ABSTRACT

The amplified region of chromosome 19q13.1-13.2 has been associated with several cancers. The well-characterized oncogene AKT2 is located in this amplicon. Two members of the same gene family (SERTAD1 and SERTAD3) are also located within this region. We report herein the genomic structure and potential functions of SERTAD3. SERTAD3 has two transcript variants with short mRNA half-lives, and one of the variants is tightly regulated throughout G1 and S phases of the cell cycle. Overexpression of SERTAD3 induces cell transformation in vitro and tumor formation in mice, whereas inhibition of SERTAD3 by small interfering RNA (siRNA) results in a reduction in cell growth rate. Furthermore, luciferase assays based on E2F-1 binding indicate that SERTAD3 increases the activity of E2F, which is reduced by inhibition of SERTAD3 by siRNA. Together, our data support that SERTAD3 contributes to oncogenesis, at least in part, via an E2F-dependent mechanism.


Subject(s)
E2F Transcription Factors/biosynthesis , Gene Expression Regulation, Neoplastic/physiology , Neoplasms, Experimental/metabolism , Neoplasms, Experimental/pathology , Oncogene Proteins/biosynthesis , Oncogene Proteins/genetics , Trans-Activators/biosynthesis , Trans-Activators/genetics , Amino Acid Sequence , Animals , Cell Line , Cell Line, Tumor , Chromosomes, Human, Pair 19/genetics , E2F Transcription Factors/metabolism , Gene Amplification , Humans , Mice , Molecular Sequence Data , NIH 3T3 Cells , Oncogene Proteins/physiology , Sequence Homology, Amino Acid , Trans-Activators/physiology
2.
Oncogene ; 25(3): 349-58, 2006 Jan 19.
Article in English | MEDLINE | ID: mdl-16186807

ABSTRACT

Treatments for hematological malignancies have improved considerably over the past decade, but the growing therapeutic arsenal has not benefited adult T-cell leukemia (ATL) patients. Oncolytic viruses such as vesicular stomatitis virus (VSV) have recently emerged as a potential treatment of solid tumors and leukemias in vitro and in vivo. In the current study, we investigated the ability of VSV to lyse primary human T-lymphotropic virus type 1 (HTLV-1)-infected T-lymphocytes from patients with ATL. Ex vivo primary ATL cells were permissive for VSV and underwent rapid oncolysis in a time-dependent manner. Importantly, VSV infection showed neither viral replication nor oncolysis in HTLV-1-infected, nonleukemic cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and in naive CD4(+) T-lymphocytes from normal individuals or in ex vivo cell samples from patients with chronic lymphocytic leukemia (CLL). Interestingly, activation of primary CD4(+) T-lymphocytes with anti-CD3/CD28 monoclonal antibody, and specifically with anti-CD3, was sufficient to induce limited viral replication and oncolysis. However, at a similar level of T-cell activation, VSV replication was increased fourfold in ATL cells compared to activated CD4(+) T-lymphocytes, emphasizing the concept that VSV targets genetic defects unique to tumor cells to facilitate its replication. In conclusion, our findings provide the first essential information for the development of a VSV-based treatment for ATL.


Subject(s)
Leukemia, T-Cell/therapy , Leukemia, T-Cell/virology , Vesicular stomatitis Indiana virus/physiology , Animals , CD4-Positive T-Lymphocytes/virology , Cell Death , Cell Line , Cell Line, Tumor , Cricetinae , Humans , Lymphocyte Activation , Virus Replication
3.
Leukemia ; 18(3): 409-14, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14712290

ABSTRACT

The effect of imatinib on chlorambucil (CLB) cytotoxicity in chronic lymphocytic leukemia (CLL) lymphocytes was examined in vitro. Imatinib sensitizes the WSU and I83 human CLL cell lines, 10- and two-fold, respectively, to CLB. Furthermore, in primary cultures of malignant B-lymphocytes obtained from 12 patients with CLL (seven patients were untreated and five treated with CLB), imatinib synergistically sensitized these lymphocytes from two- to 20-fold to CLB. This synergistic effect was observed at concentrations of imatinib (

Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Chlorambucil/pharmacology , Drug Resistance, Neoplasm , Enzyme Inhibitors/pharmacology , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Piperazines/pharmacology , Pyrimidines/pharmacology , Apoptosis/drug effects , Benzamides , Cell Cycle/drug effects , DNA-Binding Proteins/metabolism , Drug Synergism , Humans , Imatinib Mesylate , Leukemia, Lymphocytic, Chronic, B-Cell/enzymology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Phosphorylation , Protein-Tyrosine Kinases/antagonists & inhibitors , Proto-Oncogene Proteins c-abl/metabolism , Rad51 Recombinase , Tumor Cells, Cultured/drug effects , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/pathology
5.
Cancer Res ; 61(9): 3781-6, 2001 May 01.
Article in English | MEDLINE | ID: mdl-11325852

ABSTRACT

During periods of genotoxic stress, the cyclin-dependent kinase inhibitor p21waf1cip1 (hereafter referred to as p21) is transcriptionally up-regulated by the p53 tumor suppressor and subsequently plays a key role in cellular growth arrest. Investigations have also indicated that p21 may regulate nucleotide excision repair, a critical pathway that removes carcinogenic DNA damage induced by UV light and other mutagens. In this study, we examined whether low levels of endogenous p21 expression can modulate nucleotide excision repair in p53-deficient human tumor cells after UVB exposure. For this purpose, we used the well-characterized p53-/-p21+/+ adenocarcinoma cell strain DLD1 and its isogenic counterpart carrying a homozygous knockout for p21 (p53-/-p21-/- DLD1). Because p53-/-p21+/+ DLD1 expresses very low levels of endogenous p21 protein that are not up-regulated after mutagen exposure, this strain has been considered functionally p21-deficient in the cellular response to DNA damage. Nonetheless, the ligation-mediated PCR technology was used here to demonstrate, at nucleotide resolution, that p53-/-p21+/+ DLD1 excises UVB-induced cyclobutane pyrimidine dimers from the c-jun proto-oncogene at a significantly lower rate than the isogenic p53-/-p21-/- derivative. The higher efficiency of DNA repair in UVB-exposed p53-/-p21-/- DLD1 cells is accompanied by increased clonogenic survival and reduced levels of apoptosis, relative to the p53-/-p21+/+ counterpart. Our results show that ablation of p21 expression can significantly enhance the capacity of p53-deficient human tumor cells to repair UVB-induced DNA damage.


Subject(s)
Adenocarcinoma/genetics , Cyclins/physiology , DNA Damage , DNA Repair , DNA, Neoplasm/radiation effects , Tumor Suppressor Protein p53/deficiency , Adenocarcinoma/metabolism , Cyclin-Dependent Kinase Inhibitor p21 , Cyclins/biosynthesis , Cyclins/genetics , DNA, Neoplasm/genetics , Genes, jun , Humans , Polymerase Chain Reaction/methods , Proto-Oncogene Mas , Pyrimidine Dimers/genetics , Pyrimidine Dimers/metabolism , Transcriptional Activation , Tumor Cells, Cultured , Tumor Suppressor Protein p53/physiology , Ultraviolet Rays
6.
J Biomed Mater Res ; 50(3): 420-7, 2000 Jun 05.
Article in English | MEDLINE | ID: mdl-10737885

ABSTRACT

Membrane molecular weight (MW) cut-off is a critical factor for immunoprotection of transplanted microencapsulated cells as well as for graft survival. Our goal was to study dextran and protein permeation through small (<350 microm in diameter) alginate-poly-L-lysine microcapsules made with an electrostatic system. Microcapsules were packed into a column, and gel-sieving chromatography was performed with proteins and dextrans of known MW. The objectives of this study were (1) to validate this approach for the assessment of the MW cut-off of <350 microm-in-diameter microcapsules and (2) to evaluate the effect on MW cut-off of changes in experimental conditions. Elution profiles of proteins suggest that the MW cut-off of our small microcapsules lies between 14,500 and 44,000 Da whereas dextrans > or =19,000 Da were excluded. The increase in poly-L-lysine (PLL) concentration from 0.02 to 0.08% reduced the MW cut-off. Increasing the PLL MW from 11.6 to 69.6 kDa induced no change in the MW cut-off. The results also show that the method can be used to discriminate between adsorption and absorption and that insulin diffuses freely across the microcapsule membrane. This method will be useful in establishing the ideal MW cut-off, in optimizing microcapsule characteristics, and in performing routine quality controls.


Subject(s)
Alginates , Biocompatible Materials , Capsules , Islets of Langerhans Transplantation , Polylysine/analogs & derivatives , Animals , Carbohydrates , Humans , Membranes, Artificial , Particle Size , Proteins
7.
Cancer Res ; 57(16): 3390-4, 1997 Aug 15.
Article in English | MEDLINE | ID: mdl-9270002

ABSTRACT

Largely on the basis of studies using the potent clastogen ionizing radiation, it has been widely assumed that up-regulation of the cyclin-dependent kinase inhibitor p21(waf1cip1) in cultured cells exposed to DNA-damaging agents is contingent upon the presence of functional p53 tumor suppressor protein. Nevertheless, we demonstrate here that the model mutagen 254-nm UV light induces p21(waf1cip1) protein and concomitant G1 arrest in normal human skin fibroblasts, as well as in p53-deficient fibroblasts derived from cancer-prone Li-Fraumeni syndrome patients. However, as expected, following exposure to ionizing radiation, elevated p21(waf1cip1) protein levels and G1 arrest were observed only in normal fibroblasts. These data provide a prominent and clinically relevant example in which p21(waf1cip1)-mediated growth arrest occurs independently of p53 in human cells treated with a model DNA-damaging agent.


Subject(s)
Cyclins/biosynthesis , Tumor Suppressor Protein p53/radiation effects , Aneuploidy , Cell Line , Cyclin-Dependent Kinase Inhibitor p21 , DNA Damage , Fibroblasts/metabolism , Fibroblasts/radiation effects , G1 Phase/genetics , G1 Phase/radiation effects , Humans , Polyploidy , S Phase/genetics , S Phase/radiation effects , Skin/cytology , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...